Galway doctors warn current guidelines on cancer checks could risk missing tumours


A new study suggests that current guidelines that stop colorectal cancer monitoring after five years could risk missing tumours
Current medical guidelines that stop colorectal cancer monitoring after five years could risk missing late tumours and secondary growths, according to a new study led by doctors in Galway.
Researchers based at the Galway Clinic analysed the records of 188 patients who underwent surveillance following curative bowel cancer surgery in the west of Ireland between 2004 and 2023, tracking their post-operative progress for up to 18 years.
The study, published in the latest issue of the Irish Medical Journal, examined standard practices set by bodies such as the American Society of Colon and Rectal Surgeons, which currently recommend routine follow-ups for only five years.
The authors found that one in three polyps – abnormal tissue growths that can turn cancerous – were detected after the five-year surveillance period had elapsed.
Out of 33 patients who developed polyps during follow-up, 11 were diagnosed late.
In addition, 14.3% of new primary bowel cancers and 9.2% of distant metastases – cancers that had spread to other organs such as the liver or lungs – were discovered only after five years had passed.
The researchers noted that approximately 69% of medical oncologists in the country currently provide cancer surveillance for five years after surgical resection.
Overall, 14 patients developed a new primary bowel cancer during follow-up, with two of those cases occurring beyond the standard five-year window. A further 47 patients developed distant metastases, with four diagnosed after the five-year cut-off point.
“The study suggests the possibility that current ASCRS guidelines may result in a proportion of pathology occurrence to be missed in surveillance,” the authors wrote.
However, the doctors cautioned that just 1.1% of all patients in the study had developed a new primary cancer after five years, while only 2.2% developed late distant metastases.
They warned that the cost and expense of expanding routine follow-up must be balanced against the benefit, noting that the average lifetime cost of bowel cancer care was estimated at €39,000 per patient in Ireland in 2008.
The authors concluded that extended surveillance would vastly increase overall healthcare expenses and might not be practical in less-resourced healthcare economies, noting that well-designed, randomised clinical trials were required before changing national or international follow-up guidelines.
In Ireland, colorectal cancer represents the second-most-common cancer diagnosis in men and the third-most-common in women, with roughly 2,800 new cases and an average of 1,012 deaths recorded each year.
